FDA approves Lymphoseek for lymph node mapping

03/13/2013 | Medscape (free registration)

The FDA has approved Navidea Biopharmaceuticals' radioactive tracer Lymphoseek for breast cancer and melanoma intraoperative lymphatic mapping. The FDA said the tracer is the first agent for lymph node mapping to gain approval in more than three decades. "Removal and pathologic examination of lymph nodes draining a primary tumor is an important diagnostic evaluation for some patients with breast cancer or melanoma," said Dr. Shaw Chen of the FDA Center for Drug Evaluation and Research.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY